per cell (um2) (P < 0.01) compared to the control group (6 months old mice). Conclusion: These results support the hypothesis that autophagy is decreased with aging and that compromised autophagy represents a novel mechanism in the development of OA.
Purpose: Pain is the foremost clinical symptom of osteoarthritis (OA), however the processes that lead to pain in the joint are poorly understood. We have previously shown that nerve growth factor (NGF) is regulated in the joints of mice at the time they get OAinduced pain and NGF neutralisation is an effective analgesia (McNamee et al. 2010) . In pharmaceutical trials of monoclonal anti NGF antibodies, clinical efficacy in the treatment of OA pain has been demonstrated (Lane et al. 2010) but a small minority of patients developed accelerated disease, raising the possibility that analgesia per se, or anti-NGF specifically, contributes to disease progression. This might occur by removing the mechanical protection afforded by painful behaviour, or be due to a direct disease modifying effect of the antibody. The purpose of this study was to investigate the regulation of NGF in painful murine OA joints, specifically focusing on where it is regulated and its induction following mechanical injury. The dependence of NGF on FGF2, a cytokine released upon cartilage injury, was also examined. Finally, we modelled the effects of chronic NGF neutralisation or indomethacin (a non-steroidal anti-inflammatory agent) on disease progression in murine OA. Methods: Surgical joint destabilisation, a validated model of OA, was performed on 10 week old male or female mice and painful behaviour (a combination of Von Frey, cold plate sensitivity, analgesymeter and Linton incapacitance) assessed weekly. RNA was isolated from whole knee joints or micro-dissected tissues (articular cartilage, meniscus and epiphysis). For cartilage injury responses in vitro, RNA was isolated from hip epiphyses of 5 week old wild type or FGF2 knockout mice. Additional injury studies were performed on porcine cartilage that had been pre-incubated with the FGF receptor inhibitor SB402451. Anti NGF, indomethacin or relevant controls were administered to wild type OA mice from the time of pain onset for a further 6 weeks. The analgesic response to anti-NGF was measured. Joints were sectioned and scored. Results: NGF was regulated in whole murine joints at the time the mice developed pain. When micro-dissected tissues were examined separately, NGF was specifically regulated in the articular cartilage and not in the bone or meniscus. NGF was strongly regulated (>200 fold) upon in vitro cartilage injury. In vitro injury-induced NGF was dependent upon FGF2, as the induction was suppressed when FGF2 knockout cartilage was explanted, and when porcine cartilage was pre-incubated with the FGF receptor inhibitor prior to injury. Despite the dependence of NGF on FGF2 in vitro, FGF2 knockout mice still developed anti-NGF sensitive pain following joint destabilisation and pain in these mice occurred earlier than in wild type mice in keeping with their more severe cartilage injury scores (Chia et al 2009). Neutralising NGF for 6 weeks in mice with painful OA produced sustained analgesia but did not alter the severity of cartilage degradation over this time. Similarly, chronic dosing with indomethacin had no apparent disease modifying effects. Conclusions: NGF is a validated pain target in murine OA and is regulated largely within the articular cartilage in vivo and upon cartilage injury in vitro. Cartilage injury-induced NGF in vitro was strongly FGF2 dependent, but this did not seem to be the case in vivo. Indeed, FGF2 knockout mice developed earlier pain, apparently correlating with accelerated disease seen in this strain. We were unable to demonstrate any differences in disease progression between mice chronically dosed with analgesics and those with pain over this period of study. Purpose: Adamts-5 null mice are protected from cartilage degeneration and accompanying mechanical allodynia in experimental osteoarthritis induced by destabilization of the medial meniscus (DMM). A highly selective and potent monoclonal antibody (Ab) that neutralizes ADAMTS-5 was able to mimic these findings when administered prophylactically through 8 weeks post DMM surgery. The goal of the current study was to test whether this Ab can provide similar beneficial effects when administered in a therapeutic setting, i.e., after onset of joint pathological changes and mechanical allodynia. The therapeutic effects of anti-ADAMTS-5 on progression of joint damage, mechanical allodynia in the hindpaw, and concomitant molecular changes in the nociceptive pathway were analyzed. Methods: DMM surgery was performed in the right knees of 10-week old male C57BL/6 mice. Four weeks later, mice were administered weekly injections of anti-ADAMTS-5 or IgG isotype control Ab (i.p. 10 mg/kg). Untreated mice served as an additional control group. For the next 12 weeks, mice were monitored bi-weekly for mechanical allodynia in the ipsilateral hind paw using von Frey fibers and the up-down staircase technique. Sixteen weeks post DMM, mice were taken down (n¼11-12), and knees were collected for histopathology according to OARSI recommendations. Total joint score is a sum of cartilage degeneration and osteophyte formation on both the lateral and medial sides of the joint, with a maximum possible score for cartilage degeneration ¼ 60, and osteophyte formation ¼ 6 (max total joint score ¼ 66). Additionally, subchondral bone sclerosis in the medial compartment was assessed, using a bone score with a maximum score of 5. In addition, a set of n¼4 mice/treatment group were taken down 8 weeks after surgery. Ipsilateral knee innervating dorsal root ganglia (DRG) L3-L5 were harvested, and sensory neurons were isolated and cultured for 4 days. Cell culture supernatants were analyzed for the pro-algesic chemokines, MCP-1 and fractalkine, via ELISA. Results: Histopathology of the knee joint 16 weeks post surgery revealed that untreated mice developed moderate levels of cartilage degeneration and osteophyte formation (total joint score ¼ 19.3AE3.1) and subchondral bone sclerosis (bone score ¼ 2.5AE0.7). When anti-ADAMTS5 was administered beginning at 4 weeks post DMM, mice were protected against cartilage degeneration and osteophyte formation (total joint score ¼ 9.5AE2.0) (p¼0.02), but not against subchondral bone changes (bone score ¼ 2.6AE0.3) (p¼0.92) by 16 weeks post surgery. IgG isotype control Ab afforded some protection against change in the total joint score, but this was not statistically significant compared to untreated DMM mice (total joint score ¼ 13.1AE3.0) (p¼0.2). Four weeks after DMM surgery, mice presented with robust mechanical allodynia in the ipsilateral hind paw, an indicator of sensitization in the pain pathway. In untreated mice and in mice receiving IgG isotype control Ab, the allodynia was maintained through 16 weeks post surgery (p<0.0001). In mice treated with anti-ADAMTS-5, the allodynia resolved and this protection lasted through 12 weeks post surgery. By 16 weeks post surgery, mechanical allodynia had returned (p<0.05) (Fig 1) . Eight weeks after surgery, innervating DRG neurons from untreated DMM mice produced elevated levels of MCP-1 and fractalkine protein compared to naïve and sham mice. When DRG neurons were cultured from mice treated with anti-ADAMTS5 between weeks 4 and 8 post DMM, the levels of MCP-1 and fractalkine were significantly downregulated compared to untreated mice (p<0.01). This downregulation reflects decreased activation of sensory neurons and correlates with decreased mechanical allodynia after treatment with anti-ADAMTS-5. Conclusions: This study demonstrates therapeutic efficacy of a potent and selective anti-ADAMTS-5 Ab in the DMM model, when administered in early stages of disease. Therapeutic effect on cartilage degeneration, mechanical allodynia as an indicator of pain and concomitant molecular changes in sensory neurons further supports the idea that structural joint damage and development of pain are linked. These studies will help elucidate whether slowing progression of joint damage can prevent or slow the development of pain. Ongoing experiments are evaluating therapeutic effect of ADAMTS-5 blockade in late stage experimental osteoarthritis. Purpose: Inflammation and immune modulation play a role in processing of nociceptive input in the dorsal root ganglia (DRG), contributing to the development of chronic pain. Macrophage infiltration into DRG, first demonstrated in neuropathic pain models, has recently been implicated in pain and sensitization in animal models of inflammatory arthritis and osteoarthritis. The relationship between DRG macrophage infiltration, pain, and progression of joint pathology has not been studied. We investigated this relationship using a monoarticular antigen-induced arthritis (AIA) model in mice. Methods: AIA was induced by intra-articular (IA) injection of mBSA into the right knee joint of 12-week old male C57BL/6 mice immunized intradermally 3 weeks and 1 week previously with mBSA in CFA. Immunized control (IC) mice received IA saline in place of mBSA. An operator blinded to treatment assessed mechanical allodynia (von Frey) and thermal hyperalgesia (hotplate) in the hindpaw, knee hyperalgesia (Pressure application measurement), hindlimb weight distribution (forceplate) and spontaneous behaviour (LABORAS) at 0, 1, 2, 4, 6 and 8 weeks after IA injection. At 1, 4 and 8 weeks mice (AIA and IC) were sacrificed and DRG and knee joints harvested. L3-L5 DRG neurons were cultured for 4 days and supernatant MCP-1 quantified by ELISA (n ¼ 5); L2-5 DRG were immune-stained for F4/80 (n ¼ 2); knees were histologically scored for synovitis, cartilage proteoglycan (PG) loss and erosion, subchondral bone (SCB) vascular invasion and sclerosis (n¼ 6). Results: Joints in IC mice showed no histological change at any time. In AIA joints synovitis, SCB vascular invasion and cartilage PG loss peaked at W1. At W4, cartilage PG loss persisted and erosion started to develop, SCB vascular invasion decreased as SCB sclerosis started to develop, and synovitis persisted but was reduced. At W8, synovitis had significantly decreased while cartilage erosion and SCB sclerosis progressed. AIA mice developed ipsilateral secondary mechanical allodynia (W1 to W8), knee hyperalgesia (W2 to W6), and thermal hyperalgesia (by W6). AIA mice had a significant reduction in ipsilateral hindlimb weight bearing (W1), and a decrease in distance travelled and rearing frequency (W1) that resolved by W4. Interestingly, 40% of IC mice also developed ipsilateral mechanical allodynia at W1, and all IC mice had mechanical allodynia at W4, persisting until W8; these mice displayed no other pain-related behaviours. At W1 and W4, both AIA and IC mice had increased F4/80 expression in L2-L5 DRG, although greater in AIA compared to IC at W1. Four weeks post AIA, cultured DRG cells produced increased MCP-1 protein compared to age matched naïve mice. Conclusions: In summary, AIA mice developed secondary mechanical and thermal sensitization. In addition, these mice developed painrelated behaviors such as changes in weight-bearing and locomotion changes in association with progressive joint pathology over 8 weeks. This was associated with macrophage infiltration in the ipsilateral DRG L2-5 and production of MCP-1 by DRG cells. IC mice also developed secondary mechanical allodynia, in the absence of joint pathology or any other pain-related behaviours. This was accompanied by F4/80 staining in the DRG at W1 and W4. These findings suggest that intradermal immunization alone is sufficient to trigger mechanical allodynia and concomitant cellular changes in the DRG, in the absence of joint pathology. However, joint pathology occurring as a result of intra- 
